Anti-EGFR strategy for colorectal cancer: Searching for the real target

被引：0
|
作者：
Zaniboni, A. [1 ]
Meriggi, F. [1 ]
机构：
[1] Fdn Poliambulanza, UO Oncol Med, I-25100 Brescia, Italy
来源：
LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 08期
关键词：
cetuximalb; colorectal cancer; anti-EGFR therapy;
D O I：
10.2174/157018006778194673
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable.
引用
收藏
页码：541 / 543
页数：3
相关论文
共 50 条
  • [31] Activation of Signal Pathways and the Resistance to Anti-EGFR Treatment in Colorectal Cancer
    Chen, Jiezhong
    Huang, Xu-Feng
    Katsifis, Andrew
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 111 (05) : 1082 - 1086
  • [32] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Lo Nigro, Cristiana
    Ricci, Vincenzo
    Vivenza, Daniela
    Granetto, Cristina
    Fabozzi, Teresa
    Miraglio, Emanuela
    Merlano, Marco C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6944 - 6954
  • [33] MicroRNAs and response to anti-EGFR therapy in metastatic colorectal cancer.
    Blanco-Calvo, Moises
    Haz-Conde, Mar
    Rodriguez-Rigueiro, Teresa
    Figueroa, Angelica
    Reboredo, Margarita
    Medina Villaamil, Vanessa
    Lorenzo-Patino, Maria J.
    Arnal, Francisco
    Anton-Aparicio, Luis
    Alonso-Jaudenes Curbera, Guillermo
    Valladares-Ayerbes, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
    Meriggi, F.
    Di Biasi, B.
    Abeni, C.
    Zaniboni, A.
    CURRENT DRUG TARGETS, 2009, 10 (10) : 1033 - 1040
  • [35] Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer
    Noseir, Soha Hussein
    Hahn, Stephan
    Maghnouj, Abdelouahid
    Ladigan, Swetlana
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Cristiana Lo Nigro
    Vincenzo Ricci
    Daniela Vivenza
    Cristina Granetto
    Teresa Fabozzi
    Emanuela Miraglio
    Marco C Merlano
    World Journal of Gastroenterology, 2016, (30) : 6944 - 6954
  • [37] ANTI-EGFR ANTIBODY RECHALLENGE IN CHEMOREFRACTORY PATIENTS WITH METASTATIC COLORECTAL CANCER
    Kajitani, Tatsuhiro
    Makiyama, Akitaka
    Arita, Shuji
    Kumagai, Hozumi
    Oda, Hisanobu
    Shirakawa, Tsuyoshi
    Esaki, Taito
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Drivers of Secondary Resistance to Anti-Egfr Therapy in Metastatic Colorectal Cancer
    Noseir, Soha
    Hahn, Stephan
    Maghnouj, Abdelonahid
    Ladigan, Swetlana
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 219
  • [39] Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories
    Lei Cheng
    Wei Ren
    Li Xie
    Ming Li
    Jiang Liu
    Jing Hu
    Bao-Rui Liu
    Xiao-Ping Qian
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1 - 13
  • [40] Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer
    Rolfo, Christian
    Bronte, Giuseppe
    Passiglia, Francesco
    Papadimitriou, Konstantinos
    Russo, Antonio
    Peeters, Marc
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 250 - 260
12345